No Link Between Hormone Tx and All-Cause Mortality | Medpage Today – by Jeff Minerd – September 2017
This is of interest to me because I’ve been taking estrogen alone (without progesterone) for over two decades to prevent the anxiety that inevitably arises when my estrogen level falls too low (started in iatrogenic menopause).
Despite being linked with increased risk for breast cancer and stroke, hormone therapy in postmenopausal women was not associated with long-term mortality risk, data from the Women’s Health Initiative (WHI) trials showed.
In a pooled analysis of both trials, including more than 27,000 women and a cumulative 18 years of follow-up, the rate of all-cause mortality was 27.1% in the hormone therapy group and 27.6% in the placebo group. Continue reading
Association of Hormonal Contraception With Depression – JAMA Network – Charlotte Wessel Skovlund, MSc1; Lina Steinrud Mørch, PhD1; Lars Vedel Kessing, MD, DMSc2; et al. – November 2016
Question: Is use of hormonal contraception associated with treatment of depression?
Spoiler alert: the answer is a resounding “yes”. all the patients who didn’t get antidepressants (which require a pain or depression diagnosis).
Progesterone is in all birth-control pills, yet women seeking contraception are given these pills almost routinely, and never with the warning that they could cause depression.
This could explain why women tend to be more depressed than men.
Findings: In a nationwide prospective cohort study of more than 1 million women living in Denmark, an increased risk for first use of an antidepressant and first diagnosis of depression was found among users of different types of hormonal contraception, with the highest rates among adolescents. Continue reading
Your brain on PMS is like your brain on alcohol and depressants – By Cassie Werber – December 21, 2016
Recent research into hormonal contraceptives found a clear link between them and depression.
That’s hardly surprising, the researcher says, when you consider that all hormonal contraceptives contain progesterone, and some are progesterone-only.
How and why progesterone alters moods is understudied, but there’s a growing body of research, based on the results of blood tests and brain scans, conducted by Poromaa and others. One discovery from this research is that progesterone can trigger the small, almond-shaped part of the brain called the amygdala. Continue reading
What is Intractable Pain and How Does it Differ From Chronic Pain – By Forest Tennant, MD, DrPH, John Liu, MD and Laura Hermann, RN, FNP – Aug 2017
Protocols for a lifetime of pain management for patients suffering constant, incurable, excruciating, unrelenting pain.
Since IP [Intractable Pain] patients always have an underlying, incurable disease or condition causing IP, their clinical management is complex and may require a specialized clinical setting.
Just as renal failure or insulin-dependent diabetes require lifetime care by a cadre of specialized medical personnel, IP likewise requires similar lifetime care due to its incurable nature. Continue reading
3 Advances in Hormonal Pain Care — Pain News Network – By Forest Tennant, MD – Mar 2019
There are three new discoveries or innovations in hormonal pain care that I dearly love. I believe they are real trend-setters, but keep in mind that the “next big thing” may not endure.
Hormone Derivative Treatment
There are two hormonal derivatives that, in my hands, have been extremely beneficial to sub-groups of chronic pain patients.
The first is medroxyprogesterone, which is a derivative of progesterone. In my experience, medroxyprogesterone is far more potent in treating intractable pain patients than is plain progesterone. Continue reading
Oxytocin, an Opioid Alternative, Ready for Regular Clinical Use to Manage Chronic Pain –
Editor’s Memo November 2017: Dr. Tennant opens an overdue discussion on the history and future of pain medication alternatives.
…the pharmacologic properties of almost all of the currently available analgesics were established and clinically implemented more than a century ago.
Yet, a safe and effective option with a unique pharmacologic mechanism that has been right in front of us — oxytocin — has emerged as an excellent pain reliever. Continue reading
Hypermobility Syndromes Association » Hormones & Hypermobility – By Alan Hakim, Updated August 2017.
Which hormones are involved?
A hormone is sometimes described as a ‘chemical messenger’ that is secreted from a gland, circulates through the bloodstream and, finally, reaches the organ at which it is directed where it exerts its effect.
Although there are many types of hormones, all of different structures, two main groups are relevant to hypermobility. Continue reading
The Physiologic Effects of Pain on the Endocrine System – Free full-text PMC4107914 – Pain Ther. 2013 Dec – by Forest Tennant
Severe pain has profound physiologic effects on the endocrine system.
Serum hormone abnormalities may result and these serve as biomarkers for the presence of severe pain and the need to replace hormones to achieve pain control.
Initially severe pain causes a hyperarousal of the hypothalamic–pituitary–adrenal system which results in elevated serum hormone levels such as adrenocorticotropin, cortisol, and pregnenolone.
If the severe pain does not abate, however, the system cannot maintain its normal hormone production and serum levels of some hormones may drop below normal range. Continue reading
Hormone abnormalities in patients with severe and chronic pain who fail standard treatments. – PubMed – NCBI – Dec 2014
Some patients with severe and chronic pain fail to obtain adequate pain relief with standard pharmacologic treatment agents, including low to moderate dosages of opioids.
Understandably, physicians might not believe patients who claim that a standard opioid dosage is an ineffective treatment. These patients may be severely impaired, nonfunctional, and bedridden or housebound.
To help characterize these individuals and develop treatment strategies for them, a serum hormone profile consisting of Continue reading
Ehlers-Danlos Syndrome: An Emerging Challenge for Pain Management – Editor’s Memo—September 2017 – By Forest Tennant, MD, DrPH
Thank you, Dr. Tenant, for drawing attention to this terribly painful genetic syndrome that is completely ignored by so many pain specialists, even as it clearly causes increasing physical pain.
Until recently, Ehlers-Danlos Syndrome (EDS) was a name that elicited little relevance or urgency in the pain world.
Little did I realize that I had been treating more cases of EDS in patients who had been referred to my practice initially for more commonly recognized diagnoses such as fibromyalgia, spine degeneration, and resistant migraine. Continue reading